Huiping Li

6.3k total citations
250 papers, 3.7k citations indexed

About

Huiping Li is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Huiping Li has authored 250 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 119 papers in Oncology, 66 papers in Pulmonary and Respiratory Medicine and 60 papers in Molecular Biology. Recurrent topics in Huiping Li's work include Advanced Breast Cancer Therapies (49 papers), HER2/EGFR in Cancer Research (45 papers) and Cancer Treatment and Pharmacology (26 papers). Huiping Li is often cited by papers focused on Advanced Breast Cancer Therapies (49 papers), HER2/EGFR in Cancer Research (45 papers) and Cancer Treatment and Pharmacology (26 papers). Huiping Li collaborates with scholars based in China, United States and Ethiopia. Huiping Li's co-authors include Hanfang Jiang, Bin Shao, Xiaoran Liu, Eishin Yaoita, Curt D. Sigmund, Zhongsheng Tong, Guohong Song, Tadashi Yamamoto, Yutaka Yoshida and Xiaoyu Zhu and has published in prestigious journals such as Nucleic Acids Research, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Huiping Li

233 papers receiving 3.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Huiping Li China	30	1.3k	1.2k	715	601	259	250	3.7k
Premal H. Thaker United States	39	1.3k 1.0×	1.8k 1.5×	570 0.8×	561 0.9×	235 0.9×	283	5.5k
Xīn Gào United States	31	1.2k 1.0×	919 0.8×	365 0.5×	570 0.9×	423 1.6×	187	4.0k
Fang Yang China	33	1.5k 1.2×	1.4k 1.1×	932 1.3×	686 1.1×	374 1.4×	162	4.2k
Juan Peng China	31	1.2k 1.0×	775 0.6×	689 1.0×	393 0.7×	99 0.4×	180	3.7k
Wei Zheng China	36	1.6k 1.3×	896 0.7×	401 0.6×	659 1.1×	169 0.7×	190	4.5k
Juan Lin United States	26	870 0.7×	812 0.7×	360 0.5×	526 0.9×	156 0.6×	138	3.0k
Ornella Garrone Italy	27	1.2k 0.9×	2.0k 1.7×	619 0.9×	629 1.0×	352 1.4×	171	4.5k
Joo‐Hyun Nam South Korea	41	1.8k 1.4×	1.2k 1.0×	310 0.4×	747 1.2×	264 1.0×	293	7.7k
Ying Chen China	35	1.7k 1.3×	486 0.4×	648 0.9×	482 0.8×	526 2.0×	258	4.3k

Countries citing papers authored by Huiping Li

Since Specialization

Citations

This map shows the geographic impact of Huiping Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Huiping Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Huiping Li more than expected).

Fields of papers citing papers by Huiping Li

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Huiping Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Huiping Li. The network helps show where Huiping Li may publish in the future.

Co-authorship network of co-authors of Huiping Li

This figure shows the co-authorship network connecting the top 25 collaborators of Huiping Li. A scholar is included among the top collaborators of Huiping Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Huiping Li. Huiping Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liu, Jiaxuan, Huiping Li, Guohong Song, et al.. (2025). Anlotinib in combination with metronomic chemotherapy in HER2-negative metastatic breast cancer: an observational and retrospective study. BMC Cancer. 25(1). 9–9.

Juric, Dejan, Kevin Kalinsky, Nicholas C. Turner, et al.. (2024). First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses.. Journal of Clinical Oncology. 42(16_suppl). 1003–1003. 23 indexed citations

Wang, Jiani, Qingyuan Zhang, Xichun Hu, et al.. (2024). Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: An overall survival update and long-term safety from the randomised, double-blind, placebo-controlled, phase 3 trial.. Journal of Clinical Oncology. 42(16_suppl). 1050–1050.

Wang, Yongsheng, et al.. (2024). First-in-human phase 1 study of SPH4336, a novel cyclin-dependent kinase 4/6 inhibitor, in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). e15107–e15107. 1 indexed citations

Zhang, Ruyan, et al.. (2024). Real-world data of efficacy and safety of denosumab on patients with breast cancer with bone metastasis: Results from Chinese clinical experience.. Journal of Clinical Oncology. 42(16_suppl). e13103–e13103.

Wang, Xiaojia, Wěi Li, Yongmei Yin, et al.. (2023). Primary results of ELAINA: a randomized, multicenter, open-label, phase III study of the efficacy and safety of trastuzumab emtansine vs. lapatinib plus capecitabine in Chinese patients with HER2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab-based therapy. PubMed. 4. 3–3. 4 indexed citations

Hu, Chunchun, Yi Wang, Chunyang Li, et al.. (2023). Targeted sequencing and clinical strategies in children with autism spectrum disorder: A cohort study. Frontiers in Genetics. 14. 1083779–1083779. 4 indexed citations

Li, Huiping, et al.. (2023). Association between consumption of sweeteners and endometrial cancer risk: a systematic review and meta-analysis of observational studies. British Journal Of Nutrition. 131(1). 63–72. 5 indexed citations

Wang, Jiayu, Li Cai, Yanqiu Song, et al.. (2023). Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study). European Journal of Cancer. 184. 73–82. 7 indexed citations

10.

Jiang, Hanfang, Huiping Li, Guohong Song, et al.. (2023). Pegylated liposomal doxorubicin (Duomeisu®) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study. Breast Cancer Research and Treatment. 199(1). 67–79. 5 indexed citations

11.

Liu, Yin, Xiu-Zhi Zhu, Yi Xiao, et al.. (2023). Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial. Cell Research. 33(5). 389–402. 39 indexed citations

12.

Zheng, Tiantian, Xiaoran Liu, Bin Shao, et al.. (2022). Identification of mutation patterns and circulating tumour DNA-derived prognostic markers in advanced breast cancer patients. Journal of Translational Medicine. 20(1). 211–211. 12 indexed citations

13.

Jiang, Hanfang & Huiping Li. (2021). Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis. BMC Cancer. 21(1). 149–149. 154 indexed citations

14.

Bai, Han, Jianjun Yu, Shidong Jia, et al.. (2021). Prognostic Value of the TP53 Mutation Location in Metastatic Breast Cancer as Detected by Next-Generation Sequencing. Cancer Management and Research. Volume 13. 3303–3316. 8 indexed citations

15.

Zhang, Ruyan, Xiaoran Liu, Bin Shao, et al.. (2021). Clinicopathological features and prognosis of patients with pregnancy‐associated breast cancer: A matched case control study. Asia-Pacific Journal of Clinical Oncology. 17(4). 396–402. 9 indexed citations

16.

Li, Huiru, et al.. (2021). Taxonomic description of Pseudomonas rhizovicinus sp. nov., isolated from the rhizosphere of a desert shrub Haloxylon ammodendron. Antonie van Leeuwenhoek. 114(9). 1443–1452. 1 indexed citations

17.

Zhao, Qi, et al.. (2020). Biofertilizers with beneficial rhizobacteria improved plant growth and yield in chili (Capsicum annuum L.). World Journal of Microbiology and Biotechnology. 36(6). 38 indexed citations

18.

Li, Huiping, Fangfang Liu, & Wenjing Qin. (2020). Circ_0072083 interference enhances growth-inhibiting effects of cisplatin in non-small-cell lung cancer cells via miR-545-3p/CBLL1 axis. Cancer Cell International. 20(1). 78–78. 46 indexed citations

19.

Ran, Ran, Yaxin Liu, Lin Shao, et al.. (2020). <p>Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab</p>. OncoTargets and Therapy. Volume 13. 4385–4395. 6 indexed citations

20.

Tan, Wei Phin, Wei Zhang, Huiping Li, et al.. (2015). [Analysis of satisfactions for services among outpatients and inpatients at the age of equal to or more than 15 years old in Hunan province].. PubMed. 40(10). 1148–55. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact